Advertisement Pharmaceutical Business review - Page 7 of 5227 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 20, 2024

Assembly Bio and Gilead collaborate to advance antiviral therapeutic programmes

Assembly Biosciences has received an investment from Gilead Sciences, comprising a $20.1m equity investment and $10m in accelerated funding, to propel the clinical development of new antiviral therapies targeting herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).

The funding is said to propel the clinical development of new antiviral therapies. Credit: National Institute of Allergy and Infectious Diseases on Unsplash.